

Public Health Wales Awards Enteric Testing Contract to Genetic Signatures

- **Genetic Signatures wins national tender for the molecular detection of enteric pathogens for Wales**
- **Worth up to A\$1.8M per annum**
- **Seven sites to screen all patients with 3base® technology**

Genetic Signatures [ASX:GSS] has secured a three-year contract with Public Health Wales through a public tender process, to supply its *EasyScreen*™ enteric diagnostic kits and instruments to seven hospitals across Wales. The contract has a value of up to A\$1.8 million per annum and also has an option to extend for 2 years.

EasyScreen™ molecular PCR tests use Genetic Signatures' proprietary **3base**® technology to diagnose infectious diseases more accurately and rapidly than traditional methods.

According to the US Centers for Disease Control¹, there are an estimated 685 million cases of Norovirus per annum, the most common cause of gastroenteritis, representing 20% of all cases. It is prevalent in both high- and low- income countries, and results in a childhood mortality rate of approximately 50,000 each year. While outbreaks of gastroenteritis have been suppressed in the UK during the COVID pandemic, it is predicted to return rapidly to pre-pandemic levels as restrictions are relaxed. In fact, increasing numbers of outbreaks have already been reported in childcare settings and aged care facilities.

Genetic Signatures *EasyScreen*™ enteric diagnostic kits provide a flexible syndromic testing solution to detect more than 20 clinically relevant pathogenic bacteria, protozoan and viral agents that can cause gastroenteritis symptoms. Improved diagnosis of gastroenteritis enables earlier, more effective treatment, improving patient outcomes and driving significant cost savings across health systems. The *EasyScreen*™ enteric diagnostic kits have TGA and CE-IVD registrations.

"I'm pleased to welcome this partnership with Public Health Wales (PHW)", says Chief Executive, Dr John Melki. "In awarding the contract PHW noted Genetic Signatures' demonstrated flexibility regarding increasing the workload as needed plus the range of targets as factors supporting our application."

He continued: "Traction is building for non SARS-CoV-2 related business in Europe after considerable effort by the sales teams, despite travel and other restrictions. It validates our strategy of targeting high throughput hospital and pathology laboratories and government programs to drive revenue and demonstrate the cost savings, speed and accuracy of our *EasyScreen*™ testing platform."

Genetic Signatures has recently joined the BioHub Birmingham as the launchpad for a planned further expansion into Europe, the Middle East and Africa. The BioHub is the first physical footprint within the UK and Europe for Genetic Signatures. The Company continues to develop and commercialise its **3base**® technology to rapidly and cost effectively screen for a wide array of infectious pathogens. Genetic Signatures has experienced rapid growth of its respiratory diagnostic kits and has a strong pipeline of other molecular tests for global markets for major infectious diseases such as antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases, including Japanese Encephalitis.

For further information, see our website (www.geneticsignatures.com) or contact us as below:

¹ <https://www.cdc.gov/norovirus/trends-outbreaks/worldwide.html>

Dr John Melki

Chief Executive Officer

john.melki@geneticsignatures.com

T: +61 (0)2 9870 7580

Peter Manley

Chief Financial Officer

peter.manley@geneticsignatures.com

Approved for release by Board of Directors

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base**®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*™ brand. Genetic Signatures' proprietary MDx **3base**® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.